. 2025 Dec 12;13:1662346. doi: 10.3389/fpubh.2025.1662346

Table 4.

Results of interrupted time series analysis of 18 negotiated anticancer drugs.

Drug	Drug expenditure (10 thousand yuan)				DDDs (10 thousand)
Drug	Intercept β0	Baseline trend β1	Level change after MIAN β2	Trend change after MIAN β3	Intercept β0	Baseline trend β1	Level change after MIAN β2	Trend change after MIAN β3
Apatinib	775.180^***	48.630^*	−65.160	47.090	1.084^***	0.067	0.309	0.214^***
Bevacizumab	3034.890^***	129.190^*	−795.170	257.620^**	2.259^***	0.131	0.219	1.043^***
Erlotinib	903.326^***	1.041	−128.482	−8.743	1.809^***	0.022	0.147	0.155^**
Fulvestran	240.150^***	5.030	8.517	74.466^***	1.326^**	0.028	0.619	1.153^***
Lapatinib	148.196^***	2.277	−60.781	30.096^***	0.246^**	0.004	−0.081	0.102^***
Lenalidomide	176.754^*	−3.308	−179.337	110.069^***	0.133	−0.002	−0.339	0.238^***
Rituximab	7660.580^***	137.020	−372.130	−47.980	1.188^***	0.033	0.218	0.041
Nimotuzumab	1081.436^***	−4.627	241.746	54.625	1.090^***	0.020	0.650	0.154^**
Bortezomib	1586.966^***	94.929^*	149.019	−5.587	0.509^*	0.046	0.368	0.087^*
Trastuzumab	6294.500^***	138.700	−1968.800	258.100	5.927	0.246	−0.887	1.963^**
Sorafenib	1562.260^***	11.520	−366.910	154.350	0.970^***	0.007	0.053	0.257^***
Everolimus	155.586^***	−2.508	−0.415	7.738	0.314^***	−0.005	0.068	0.034^**
Recombinant human endostatin	2028.230^***	25.320	−72.370	36.030	1.396^***	0.024	0.166	0.076
Chidamide	−5.779	1.944	2.520	29.036^***	−0.006	0.002	0.010	0.045^***
Abiraterone	75.260	11.680	−189.780	241.390^***	0.061	0.010	−0.223	0.438^***
Shenyi Capsule	1334.542^***	−7.976	−77.588	−59.365^*	32.651^***	−0.031	2.290	−1.483^*
Compound realga natural indigo tablets	49.786^**	−1.299	20.780	3.343	0.1387^**	−0.003	0.088	0.017
Astragalus polysaccharide for injection	490.004^***	−20.756^*	−86.835	36.175^**	0.939^***	−0.039	−0.154	0.121^***

***p < 0.01; **p < 0.01; *p < 0.05.